Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome

Journal of the American College of Cardiology

Volumn 43, Issue 11, 2004, Pages 1982-1988

  Xiao, Zihui ^a   Théroux, Pierre ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

ACS; acute coronary syndrome; adenosine diphosphate; ADP; FITC; fluorescein isothiocyanate; Ig; immunoglobulin; PAR; platelet poor plasma; platelet rich plasma; PMN; polymorphonuclear cell; PPP; protease activated receptor; PRP; TRAP

Indexed keywords

ACETYLSALICYLIC ACID; CD40 LIGAND; CLOPIDOGREL; PADGEM PROTEIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HEART MUSCLE ISCHEMIA; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEPTOR BLOCKING; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ASPIRIN; BLOOD PLATELETS; CD40 LIGAND; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 2542488125     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.071     Document Type: Article

References (38)

1. Weber A.A., Reimann S., Schror K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol. 126:1999;415-420
2. The CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348:1996;1329-1339
3. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 345:2001;494-502
4. Bhatt D.L., Bertrand M.E., Berger P.B., et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 39:2002;9-14
5. Steinhubl R.R., Berger P.B., Mann T. III, et al. CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. JAMA. 288:2002;2411-2420
6. Payne D.A., Hayes P.D., Jones C.I., Belham P., Naylor A.R., Goodall A.H. Combined therapy with clopidogrel and aspirin significantly increases the bleeding time through a synergistic antiplatelet action. J Vasc Surg. 35:2002;1204-1209
7. Gurbel P.A., Bliden K.P., Hiatt B.L., O'Connor C.M. Clopidogrel for coronary stenting Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 107:2003;2908-2913
8. Evangelista V., Manarini S., Sideri R., et al. Platelet/polymorphonuclear leukocyte interaction P-selectin triggers protein-tyrosine phosphorylation- dependent cd11b/cd18 adhesion: role of psgl-1 as a signaling molecule. Blood. 93:1999;876-885
9. Scholz T., Zhao L., Temmler U., Bath P., Heptinstall S., Losche W. The GP IIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro. Platelets. 13:2002;401-406
10. Henn V., Slupsky J.R., Grafe M., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594
11. Lindmark E., Tenno T., Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol. 20:2000;2322-2328
12. Ott I., Neumann F.J., Gawaz M., Schmitt M., Schomig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation. 94:1996;1239-1246
13. Sarma J., Laan C.A., Alam S., Jha A., Fox K.A., Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation. 105:2002;2166-2171
14. Furman M.I., Barnard M.R., Krueger L.A., et al. Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol. 38:2001;1002-1006
15. Rinder C.S., Bonan J.L., Rinder H.M., Mathew J., Hines R., Smith B.R. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood. 79:1992;1201-1205
16. Mickelson J.K., Lakkis N.M., Villarreal-Levy G., Hughes B.J., Smith C.W. Leukocyte activation with platelet adhesion after coronary angioplasty A mechanism for recurrent disease? J Am Coll Cardiol. 28:1996;345-353
17. Schonbeck U., Libby P. CD40 signaling and plaque instability. Circ Res. 89:2001;1092-1103
18. Storey R.F., Judge H.M., Wilcox R.G., Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost. 88:2002;488-494
19. Klinkhardt U., Graff J., Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther. 71:2002;176-185
20. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:2001;672-674
21. Muller I., Seyfarth M., Rugiger S., et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 85:2001;92-93
22. Moshfegh K., Redondo M., Julmy F., et al. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction Enhanced inhibitory effects of combination therapy. J Am Coll Cardiol. 36:2000;699-705
23. Storey R.F., Sanderson H.M., White A.E., May J.A., Cameron K.E., Heptinstall S. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 110:2000;925-934
24. Trumel C., Payrastre B., Plantavid M., et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide-3 kinase. Blood. 94:1999;4156-4165
25. Ravanat C., Leon C., Cazenave J.P., Gachet C. Involvement of the P2cyc but not the P2Y1 ADP receptor in the phosphatidylserine exposure of activated platelets. Haematologica. 85:(Suppl):2000;94
26. Peter K., Schwarz M., Ylanne J., et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood. 92:1998;3240-3249
27. Xiao Z., Théroux P., Frojmovic M. Modulation of platelet-neutrophil interaction with pharmacological inhibition of fibrinogen binding to platelet GP IIb/IIIa receptor. Thromb Haemost. 81:1999;281-285
28. Cox D., Smith R., Quinn M., Theroux P., Crean P., Fitzgerald D.J. Evidence of platelet activation during treatment with a GP IIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol. 36:2000;1514-1519
29. Gurbel P.A., Malinin A.I., Callahan K.P., Serebruany V.L., O'Connor C.M. Effect of loading with clopidogrel on platelet aggregation at the time of coronary stenting on platelet aggregation and glycoprotein IIb/IIIa expression and platelet-leukocyte aggregate formation. Am J Cardiol. 90:2002;312-315
30. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina Possible reflection of t lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 100:1999;614-620
31. Hermann A., Rauch B.H., Braun M., Schror K., Weber A.A. Platelet CD40 ligand (CD40L)-subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets. 12:2001;74-82
32. Seyfarth H.J., Koksch M., Roethig G., et al. Effect of 300- and 450-mg clopidogrel loading doses on membrane and soluble P-selectin in patients undergoing coronary stent implantation. Am Heart J. 143:2002;118-123
33. Eikelboom J.W., Weitz J.I., Budaj A., et al. Clopidogrel does not suppress blood markers of coagulation activation in aspirin-treated patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 23:2002;1771-1779
34. Xiao Z., Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 97:1998;251-256
35. Wei C., Lau W.C., Waskell L.A., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation A new drug-drug interaction. Circulation. 107:2003;32-37
36. Serebruany V.L., Steinhubl S.R., Hennekens C.H. Are antiplatelet effects of clopidogrel inhibited by atorvastatin? A research question formulated but not yet adequately tested. Circulation. 107:2003;1568-1569
37. Gachet C. ADP receptors of platelets and their inhibition. Thromb Haemost. 86:2001;222-232
38. Turner N.A., Moake J.L., McIntire L.V. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 98:2001;3340-3345